BIOLASE, INC. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2010-12-23: Form 8-K; Period of report 2010-12-23; Description 1.01 Entry into a Material Definitive Agreement; Details 1.01.
- 2010-12-06: Form 8-K; Period of report 2010-11-30; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 5.02.
- 2010-11-03: Form 8-K; Period of report 2010-11-01; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 5.02.
- 2010-11-02: Form 8-K; Period of report 2010-11-02; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2010-12-23 | 8-K | 2010-12-23 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | htm_40200.htm |
| 2010-12-06 | 8-K | 2010-11-30 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On November 30, 2010, the Board of Directors (the "Board") of Biolase Technology, Inc. (the "Company") appointed Frederick D. Furry as Chief Financial Officer of the Company. | htm_39959.htm |
| 2010-11-03 | 8-K | 2010-11-01 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On November 1, 2010, the Board of Directors (the “Board”) of Biolase Technology, Inc. (the “Company”) elected Mr. Gregory E. Lichtwardt, age 56, to the Board of Directors and appointed Mr. Lichtwardt to the Audit Committee of the Board. | c07748e8vk.htm |
| 2010-11-02 | 8-K | 2010-11-02 | 2.02 Results of Operations and Financial Condition | 2.02 On November 2, 2010, Biolase Technology, Inc. issued a press release announcing its financial results for the third quarter ended September 30, 2010. | c07636e8vk.htm |
| 2010-09-29 | 8-K | 2010-09-23 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant | 1.01 Entry into a Material Definitive Agreement. 2.03 The information included in Item 1.01 of this Current Report on Form 8-K regarding the Security Agreement undertaking is incorporated by reference into this Item 2.03. | htm_39184.htm |
| 2010-09-13 | 8-K | 2010-09-07 | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | 3.01 On September 7, 2010, Biolase Technology, Inc. (the "Company") received a deficiency letter from The Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company was not in compliance with Listing Rule 5605 (the "Rule") due to the vacancies created by the resignations from our Audit Committee of: (i) Mr. Gregory D. Waller on August 22, 2010 and (ii) Mr. James R. Largent on August 26, 2010. | htm_39008.htm |
| 2010-08-30 | 8-K | 2010-08-27 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On August 27, 2010, the Board of Directors (the "Board") of Biolase Technology, Inc. (the "Company") appointed Federico Pignatelli as interim Chief Executive Officer of the Company. | htm_38869.htm |
| 2010-08-27 | 8-K | 2010-08-24 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 Effective as of August 24, 2010, David M. Mulder resigned from his positions as Chairman, Chief Executive Officer, and President of Biolase Technology, Inc. (the "Company"). | htm_38864.htm |
| 2010-08-26 | 8-K | 2010-08-22 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On August 22, 2010, Mr. Gregory D. Waller resigned from the Biolase Technology, Inc. (the "Company") Board of Directors. | htm_38858.htm |
| 2010-08-24 | 8-K | 2010-08-18 | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | 3.01 On August 18, 2010, Biolase Technology, Inc. (the "Company") received a staff deficiency letter from The NASDAQ Stock Market indicating that based on the Company’s stockholders’ equity as reported in its Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2010, the Company does not comply with the minimum stockholders’ equity requirement of $2.5 million for continued listing on The NASDAQ Capital Market as set forth in NASDAQ Listing Rule 5550(b)(1). | htm_38829.htm |
| 2010-08-20 | 8-K | 2010-08-16 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | htm_38799.htm |
| 2010-08-19 | 8-K | 2010-08-13 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | htm_38785.htm |
| 2010-08-17 | 8-K | 2010-08-17 | 2.02 Results of Operations and Financial Condition | 2.02 On August 17, 2010, Biolase Technology, Inc. issued a press release announcing its financial results for the second quarter ended June 30, 2010. | htm_38772.htm |
| 2010-08-04 | 8-K | 2010-07-29 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On July 29, 2010, the Board of Directors (the "Board") of Biolase Technology, Inc. (the "Company") made certain appointments to the Audit, Compensation, Nominating and Corporate Governance, and Quality and Compliance Committees of the Board. | htm_38596.htm |
| 2010-07-22 | 8-K | 2010-07-17 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On July 17, 2010, the Board of Directors (the “Board”) of Biolase Technology, Inc. (the “Company”) elected Alexander K. Arrow, M.D., CFA, age 39, to the Board of Directors. | a56794e8vk.htm |
| 2010-07-12 | 8-K | 2010-07-06 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 Effective as of July 6, 2010, Brett L. Scott resigned from his position as Chief Financial Officer of Biolase Technology, Inc. (the "Company"). | htm_38297.htm |
| 2010-07-07 | 8-K | 2010-07-02 | 1.01 Entry into a Material Definitive Agreement; 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | 1.01 Entry into a Material Definitive Agreement. 5.03 In conjunction with the Settlement Agreement, the Company amended and restated its bylaws on July 2, 2010. | htm_38242.htm |
| 2010-06-11 | 8-K | 2010-06-10 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events | 5.02 On June 10, 2010, a special committee of the board of directors (the “Board”) of Biolase Technology, Inc. (“Biolase” or the “Company”) consisting of all of its independent directors and David M. Mulder, Biolase’s Chief Executive Officer, unanimously voted to terminate and remove Federico Pignatelli from the office of President of the Company, effective immediately. 8.01 Mr. Pignatelli, in his prior capacity as President of the Company, sent a letter to the Secretary of the Company on June 4, 2010, which was subsequently revised and reissued on June 7, 2010, purporting to call a special meeting of the Company’s stockholders to be held at 11:00 a.m. | a56474e8vk.htm |
| 2010-06-09 | 8-K | 2010-06-09 | 7.01 Regulation FD Disclosure | 7.01 On June 9, 2010, David M. Mulder, Chief Executive Officer of Biolase Technology, Inc. (the “Company”), and Brett L. Scott, Chief Financial Officer of the Company, will deliver a presentation at the Needham and Company 9th Annual Healthcare Conference in New York City, that will include a written communication comprised of slides. | a56444e8vk.htm |
| 2010-06-03 | 8-K | 2010-05-27 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 2.03 On May 27, 2010, Biolase Technology, Inc. (the "Company") entered into a Loan and Security Agreement (the "Loan Agreement") with MidCap Financial, LLC, a Delaware limited liability company, and Silicon Valley Bank, a California corporation (collectively, the "Lenders") for term loan funding of up to $5 million. 8.01 On May 28, 2010, the Company issued a press release announcing the signing of the Loan Agreement disclosed in Item 2.03 above. | htm_37893.htm |
| 2010-05-26 | 8-K | 2010-05-20 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | htm_37785.htm |
| 2010-05-17 | 8-K | 2010-05-17 | 2.02 Results of Operations and Financial Condition | 2.02 On May 17, 2010, Biolase Technology, Inc. issued a press release announcing its financial results for the first quarter ended March 31, 2010. | htm_37636.htm |
| 2010-05-13 | 8-K | 2010-05-12 | 7.01 Regulation FD Disclosure | 7.01 Biolase Technology, Inc. (the "Company"), has made available a pre-recorded presentation by David M. Mulder, the Company's Chief Executive Officer, discussing, among other things, the Company’s top-line restructuring and 2010 plans, which such presentation will be presented live by Mr. Mulder on May 13, 2010, at the TechAmerica Growth Cap Financial Conference, in San Francisco, California. | htm_37590.htm |
| 2010-05-07 | 8-K | 2010-05-05 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.07 Submission of Matters to a Vote of Security Holders | 5.02 On May 5, 2010, Dr. Daniel S. Durrie and Mr. Neil J. Laird resigned from the Biolase Technology, Inc. (the "Company") Board of Directors. 5.07 On May 5, 2010, the 2010 Annual Meeting of Stockholders of the Company was held at the Company's headquarters, 4 Cromwell, Irvine, California. | htm_37518.htm |
| 2010-05-05 | 8-K | 2010-05-04 | 7.01 Regulation FD Disclosure | 7.01 Biolase Technology, Inc. (the “Company”) expects to make a slide presentation at its annual meeting of stockholders, scheduled to be held on May 5, 2010. | a56031e8vk.htm |
| 2010-04-15 | 8-K | 2010-04-07 | 8.01 Other Events | 8.01 On April 7, 2010, Biolase Technology, Inc. (the "Company") received notice that Discus Dental LLC and Zap Lasers LLC together filed a complaint against the Company in the United States District Court for the Central District of California. | htm_37143.htm |
| 2010-03-18 | 8-K | 2010-03-18 | 2.02 Results of Operations and Financial Condition | 2.02 On March 18, 2010, Biolase Technology, Inc. (the "Company") issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2009. | htm_36799.htm |
| 2010-03-11 | 8-K | 2010-03-09 | 1.01 Entry into a Material Definitive Agreement; 2.02 Results of Operations and Financial Condition | 1.01 Entry into a Material Definitive Agreement. 2.02 On March 10, 2009, the Company issued a press release announcing, among other things, preliminary financial results for the fourth quarter of 2009. | htm_36687.htm |
| 2010-02-25 | 8-K | 2010-02-24 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 7.01 Regulation FD Disclosure; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 2.03 The information included in Item 1.01 of this Current Report on Form 8-K regarding the Security Agreement undertaking is incorporated by reference into this Item 2.03. 7.01 Commencing on February 25, 2010, David M. Mulder, Chief Executive Officer of the Company, and Brett L. Scott, Chief Financial Officer, will deliver presentations to investors that will include a written communication comprised of slides. 8.01 On February 24, 2010, the Company issued a press release announcing the global launch of the iLase personal diode laser for the dental market. | a55314e8vk.htm |
| 2010-02-22 | 8-K | 2010-02-16 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant | 1.01 Entry into a Material Definitive Agreement. 2.03 The information included in Item 1.01 of this Current Report on Form 8-K regarding the Security Agreement undertaking is incorporated by reference into this Item 2.03. | htm_36410.htm |
| 2010-02-04 | 8-K | 2010-01-31 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | htm_36147.htm |
| 2010-01-13 | 8-K | 2010-01-13 | 7.01 Regulation FD Disclosure | 7.01 On January 13, 2010, David M. Mulder, Chief Executive Officer of Biolase Technology, Inc. (the “Company”), and Brett L. Scott, Chief Financial Officer of the Company, will deliver a presentation at the 12th Annual Needham Growth Stock Conference that will include a written communication comprised of slides. | a54832e8vk.htm |